A 12-Week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel-group Phase 2 Dose Selection Study of Lorcaserin Hydrochloride, an Oral 5-HT2C Receptor Agonist for Smoking Cessation

Trial Profile

A 12-Week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel-group Phase 2 Dose Selection Study of Lorcaserin Hydrochloride, an Oral 5-HT2C Receptor Agonist for Smoking Cessation

Completed
Phase of Trial: Phase II

Latest Information Update: 20 May 2015

At a glance

  • Drugs Lorcaserin (Primary)
  • Indications Smoking withdrawal
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 20 May 2015 Results presented at the 111th International Conference of the American Thoracic Society.
    • 04 Nov 2014 Results published in an Eisai media release.
    • 04 Nov 2014 Primary endpoint has been met (abstinence from smoking, defined as no reported smoking or other nicotine use and an end-expiratory exhaled carbon monoxide measurement of no more than 10 parts per million), according to an Eisai media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top